Clene Inc.
CLNNAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| May 2, 2022 | Canaccord Genuity | Sumant Kulkarni | $10.00(-32%) | $14.65 | Pulse 2.0 |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Oct 19, 2026 |
| HC Wainwright & Co. | maintain | Buy | May 4, 2026 |
| D. Boral Capital | maintain | Buy | May 4, 2026 |
| Canaccord Genuity | maintain | Buy | Mar 13, 2026 |
| D. Boral Capital | maintain | Buy | Mar 12, 2026 |
| D. Boral Capital | maintain | Buy | Jan 9, 2026 |
| D. Boral Capital | maintain | Buy | Dec 10, 2025 |
| D. Boral Capital | maintain | Buy | Dec 3, 2025 |
| D. Boral Capital | maintain | Buy | Nov 17, 2025 |
| D. Boral Capital | maintain | Buy | Sep 25, 2025 |
| Benchmark | maintain | Buy | Sep 10, 2025 |
| D. Boral Capital | maintain | Buy | Aug 21, 2025 |
| Canaccord Genuity | maintain | Buy | Aug 18, 2025 |
| D. Boral Capital | maintain | Buy | Aug 14, 2025 |
| D. Boral Capital | maintain | Buy | Jul 18, 2025 |
| D. Boral Capital | maintain | Buy | Jun 30, 2025 |
| Benchmark | maintain | Buy | May 8, 2025 |
| D. Boral Capital | maintain | Buy | May 8, 2025 |
| D. Boral Capital | maintain | Buy | Apr 8, 2025 |
| HC Wainwright & Co. | maintain | Buy | Apr 8, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 25, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 24, 2025 |
| D. Boral Capital | maintain | Buy | Mar 24, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 12, 2025 |
| D. Boral Capital | maintain | Buy | Mar 12, 2025 |
Earnings History
Next report: Mar 11, 2027 · EPS est. $-0.51| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 4, 2026 | $0.05 | $-0.45 | $56.0K | $70.0K |
| Aug 14, 2026 | $-1.08 | $-0.37 | $90.0K | $61.0K |
| May 14, 2026 | $-0.69 | $-0.50 | $15.0K | $50.8K |
| Mar 12, 2026 | $-0.93 | $-0.74 | $77.0K | $26.0K |
| Nov 13, 2025 | $-0.85 | $-0.60 | $15.0K | $64.3K |
| Aug 14, 2025 | $-0.78 | $-0.49 | $27.0K | $65.4K |
| May 7, 2025 | $-0.09 | $-0.95 | $81.0K | $75.7K |
| Mar 24, 2025 | $-1.67 | $-1.21 | $91.0K | $138.3K |
News
Clene Inc. (CLNN) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of a loss of $0.46 per share. This compares to a loss of $0.85 per share a year ago.
SALT LAKE CITY, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN), a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, today announced its third quarter 2026 financial results and provided updates on its CNM-Au8 programs.
SALT LAKE CITY, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN), a clinical-stage biotechnology company focused on revolutionizing the treatment of neurodegenerative diseases, announced that it has submitted a New Drug Application (NDA) earlier in October to the U.S. Food and Drug Administration (FDA) seeking accelerated approval of CNM-Au8® for the treatment of amyotrophic lateral sclerosis (ALS).
Clene (NASDAQ: CLNN - Get Free Report) and Addex Therapeutics (NASDAQ: ADXN - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings and valuation. Profitability This table compares Clene and Addex Therapeutics'
Clene NASDAQ: CLNN said it plans to submit a new drug application to the U.S. Food and Drug Administration at the beginning of the fourth quarter for CNM-Au8, its investigational treatment for amyotrophic lateral sclerosis, or ALS.
Clene Inc. (NASDAQ: CLNN - Get Free Report) has earned a consensus rating of "Moderate Buy" from the seven brokerages that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation and six have given a buy recommendation to the company. The average 1-year price objective among brokers that
SALT LAKE CITY, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) today announced that management will participate at the 5th Annual ROTH Healthcare Opportunities Conference and at the Lytham Partners Investor Conference Fall Event and host 1x1 investor meetings at both conferences.
SALT LAKE CITY, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN), a clinical-stage biotechnology company focused on ALS, today announced the closing of a registered direct offering of common stock to existing shareholders, including insiders, with total gross proceeds of $4 million.
Investment led by Clene's Chairman of the Board of Directors, alongside founding investor Kensington Capital Holdings, Clene's Chief Executive Officer and other existing shareholders $4 million registered direct offering priced at market under Nasdaq rules Proceeds are expected to be sufficient to fund the Company to mid-first quarter 2027 SALT LAKE CITY, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN), a clinical-stage biotechnology company focused on ALS, today announced the prici…
Canopy Growth (NASDAQ: CGC - Get Free Report) and Clene (NASDAQ: CLNN - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk. Valuation and Earnings This table compares Canopy Growth
SALT LAKE CITY, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) today announced that management will present at the 2026 Cantor Global Healthcare Conference and at the H.C.
Clene NASDAQ: CLNN is preparing to submit a New Drug Application, or NDA, seeking accelerated approval for CNM-Au8 in amyotrophic lateral sclerosis, or ALS, after completing additional analyses requested by the U.S. Food and Drug Administration, President and CEO Rob Etherington said in an interview.
MIAMI, Aug. 19, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth. com a leading independent small cap media portal announces the schedule of the 95th Emerging Growth Conference on August 19 and 20, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products and services, focused strategy, execution, and the overall potential for long-term growth.
SALT LAKE CITY, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) today announced that management will present at the Emerging Growth Conference. Virtual Presentation Details Date: August 19, 2026 Time of Presentation: 3:10 p.m.
Clene Inc. (CLNN) came out with a quarterly loss of $0.6 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to a loss of $0.78 per share a year ago.
Clene expects to submit a New Drug Application for CNM-Au8® in ALS under the accelerated approval pathway in early fourth quarter of 2026 Clene announces survival and functional benefit in CNM-Au8-treated patients whose NfL declined or stabilized SALT LAKE CITY, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) today announced its second quarter 2026 financial results and provided recent updates on its CNM-Au8 programs. “We plan to submit our new drug application (NDA) for CNM-Au8 unde…
Clene NASDAQ: CLNN said it is preparing to submit a new drug application, or NDA, in early fourth quarter for CNM-Au8 as a potential treatment for amyotrophic lateral sclerosis, following a series of meetings with the U.S. Food and Drug Administration.